Piroxicam pharmacokinetics

Hobbs DC, Twomey TM Piroxicam pharmacokinetics in man aspirin and antacid interaction studies. (1979) 19, 270-81. 

All piroxicam batches were manufactured in compliance with Good Manufacturing Practices, and three formulations having fast, moderate, and slow dissolution were chosen for comparison to a lot of the innovator s product in a human bioavailability study [100]. The resulting pharmacokinetic data provided still another opportunity to examine the effects of formulation variables. To explore the relationship between the in vitro dissolution of piroxicam from these capsules and in vivo absorption, Polli [ 102] used the following previously described [145] deconvolution-based model ... 

Roskos LK, Boudinot ED Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. Biopharm Drug Dispos 11 215-225, 1990 Rosier M, Anand R, Cici-Sain A, et al Efficacy and safety of rivastigmine in patients with Alzheimer s disease international randomized controlled trial. BMJ 318 633-640, 1999... 

In 16 healthy volunteers there were no important pharmacokinetic changes when a single dose of ciclosporin was taken during steady-state administration of aspirin, indometacin, or piroxicam, but there was an interaction with diclofenac, whose AUC was doubled in the presence of ciclosporin (46). 

In healthy volunteers, steady-state fondaparinux did not alter the pharmacodynamic effects of a single dose of piroxicam 20 mg (23). Piroxicam did not alter the pharmacokinetics of fondaparinux. 

Ollier C, Faaij RA, Santoni A, Duvauchelle T, van Haard PM, Schoemaker RC, Cohen AF, de Greef R, Burggraaf J. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002 41(Suppl 2) 31-7. 

Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, Sany J, Bressolle F. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995 34(5) 421-8. 

Tenoxicam is a piroxicam analogue with a half-life of 75 hours. Whether the differences in pharmacokinetics in elderly patients have any clinical significance is unknown (SEDA-12, 93). 

An additional important finding from this study was the hme of onset of acute renal decompensation. Ibuprofen-induced renal failure occurred rapidly (within 8 days), but piroxicam and sulindac were not associated with any deterioration of renal function during the 11-day treatment period [39]. A pharmacokinetic analysis of the drugs used in these patients suggested the following Ibuprofen, which has a short elimination half-life, reached maximum serum concen-... 

Wanwimolruk, S. Wanwimolruk, S.Z. Zoest, A.R. Sensitive HPLC assay for ketoprofen in human plasma and its application to pharmacokinetic study. J.Liq.Chromatogr., 1991, 14, 3685—3694 [plasma pharmacokinetics piroxicam (IS) microbore LOD 50 ng/mL]... 

Troconiz, J.I. Lopez-Bustamante, L.G. Fos, D. High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals. Arzneimittelforschung, 1993, 43, 679-681... 

Macek, J. Vacha, J. Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography. J.Chromatogr., 1987,420, 445-449 [column temp 35 glass column LOD 150 ng/mL pharmacokinetics simultaneous antipyrine, diclofenac, hydroxychloroquine, ibuprofen, isoxicam, plaquenil, sulfamethazine]... 

As another parameter to alter the pharmacodynamic prohle of desmopressin, a sex difference is most important. In 2004, Odeberg et al. demonstrated that there was a sex difference in a human pharmacokinetic (PK) and pharmacodynamic (PD) study [214], where desmopressin was administered intravenously as a single dose (for the PK study, a 2-pg dose for the PD study, a 0.2-pg dose), and parameters for urine flow and urine osmolality were estimated. The pharmacokinetics of desmopressin after a fixed bofus injection were influenced neither by piroxicam nor by sex of subjects. However, the pharmacodynamics of desmopressin showed a sex difference where females exhibited a more pronounced antidiuretic effect than males, which was statistically signihcant when the effects were submaximal (>4.5h after dose). The sex differences were diminished after pretreatment with an NSAID, piroxicam, indicating a prostaglandin PGE2-mediated mechanism. 

Odeberg J M, Callreus T, Lundin S, et al. (2004). A pharmacokinetics and pharmacodynamics study of desmopressin Evaluationg sex differences and the effect of pretreatment with piroxicam, and further validation of an indirect response model. J. Pharm. Pharmacol. 56 1389-1398. 

The pharmacokinetics of lomoxicam, meloxicam, piroxicam and tenoxicam were not affected by aluminium/magnesium hydroxide antacids. Lomoxicam pharmacokinetics were also not altered by tripotassium dicitratobismuthate or aluminium hydroxide with calcium carbonate. 

Ishizaki T, Nomura T, Abe T. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting andpostyrandial states inrawi. JPharmacokinetBiopharm (1979)7,369-81. 

Tilstone WJ, Lawson DH, Omara F, Cunningham F. The steacty-state pharmacokinetics of piroxicam effect of food and iron Eur J Rheumatol Inflamm (1981)4, 309-13. 

In 10 healthy subjects cimetidine 300 mg four times daily for 7 days slightly increased the half-life and the AUC of a single 20-mg dose of piroxicam by 8% and 16%, respectively. Another study found that cimetidine caused a 15% rise in the AUC of piroxicam. In 12 healthy subjects the half-life and AUC of a single-dose of piroxicam were increased by 41% and 31%, respectively, by cimetidine 200 mg three times daily, and the plasma levels were raised accordingly for example, at 4 hours they were raised by almost 25%. Ranitidine was not found to affect the pharmacokinetics of piroxicam. No clinically significant changes occurred in the steady-state serum levels of piroxicam in a further study when either cimetidine or nizatidine were given. ... 

Freeman DJ, Danter WR, Carruthers SG. Pharmacokinetic interaction between cimetidine and piroxicam in normal subjects. ClinlnvestMed 9%%) 11, C19. 

Dixon JS, Lacey LF, Pickup ME, Langley SJ, Page MC. A lack of pharmacokinetic interaction between ranitidine and piroxicam. EurJ Clin Pharmacol (1990) 39, 583-6. 

The antiplatelet activity and the pharmacokinetics of aspirin do not appear to be affected by omeprazole. There was no clinically relevant pharmacokinetic interaction between omeprazole and diclofenac, enteric-coated ketoprofen, naproxen or piroxicam, or between pantoprazole and diclofenac or naproxen, or between esomeprazole and naproxen or rofecoxib. 

Omeprazole 20 mg daily given to 24 healthy subjects with piroxicam 10 mg daily for one week had no effect on the pharmacokinetics of either drug. ... 

A study in 6 healthy subjects given a single 40-mg dose of piroxicam before and after a 7-day course of rifampicin 600 mg daily found that rifampicin did not significantly alter the pharmacokinetics of piroxicam. ... 

In another study, piroxicam 20 mg daily for 10 days was given to 12 healthy subjects with fondaparinux 10 mg daily starting on day 7. Both drugs were also given alone. Piroxicam had no effect on fondaparinux pharmacokinetics, and had no effect on the small prolongation of aPTT seen with fondaparinux. There was no difference in bleeding time between the treatments. ... 

The pharmacological studies described show that the pharmacokinetics of fondaparinux are not changed by aspirin and piroxicam, and that there is only a minor increase in bleeding time. Nevertheless, the manufacturers of... 

No effect on the pharmacokinetics of either free or bound methotrexate was seen in 20 patients with rheumatoid arthritis taking methotrexate 10 mg weekly when they were given piroxicam 20 mg daily for at least 15 days. " In another study in 10 patients with rheumatoid arthritis taking methotrexate 7.5 to 17.5 mg weekly, methotrexate oral and renal clearance were similarly unaffected by piroxicam 20 mg daily. ... 

A study in 6 healthy subjeets given atenolol 100 mg daily and piroxicam 20 mg daily for 7 days found no pharmacokinetic interaction. An associated study in another 6 healthy subjeets given metoprolol 100 mg twice daily and piroxicam 20 mg daily for 7 days found that metoprolol levels were increased by piroxicam, but not to a statistically significant extent. ... 

Spahn H, Langgutii P, Krauss D, Kirch W, Mutschler E. Pharmacokinetics of atenolol and metoprolol administered together with piroxicam. yfrc/iP/ianw (Wienheim) (1987) 320,103-7. 

In 10 patients taking digoxin for mild heart failure, piroxicam 10 or 20 mg daily for 15 days had no effect on the steady-state digoxin levels, nor were eonsistent effects seen on the pharmacokinetics of digoxin. Piroxicam 20 mg daily for 10 days was found to have no effect on serum digoxin levels in 6 healthy subjects. ... 

Piroxicam is reported to have increased the serum creatinine levels ofa patient with rheumatoid arthritis by an unknown amount (but classed as a significant adverse event). This resolved when the piroxicam was withdrawn. A study in healthy subjects given piroxicam 20 mg daily for 11 days and a single 300-mg dose of ciclosporin on day 10 found no clinically relevant pharmacokinetic interaction. ... 

Aspirin and many other NSAE)s can cause bronchoconstriction in some asthmatic patients. Celecoxib, etoricoxib and meloxicam do not usuaiiy cause bronchospasm in aspirin or NSAEJ-sensitive patients. Aspirin, nimesulide and piroxicam appear not to alter theophyiiine pharmacokinetics. 

---